צמיחת הכנסות ב-12 חודשים נגררים: Centessa Corp (CNTA)

Centessa Pharmaceuticals (CNTA) employs a portfolio approach to develop biotech startups specializing in hematology and rare pathologies. This decentralized structure enables the creation of innovative orexin agonists for the treatment of narcolepsy. The success of this asset-centric model depends on FDA approval. This chart illustrates the year-over-year revenue dynamics for the last 12 months based on GURU.Markets data, where the figure is recorded at -100.20.
Centessa Corp (CNTA) - פילוחי מדדים ודוחות פיננסיים

For Centessa Pharmaceuticals (CNTA), whose revenues depend on the commercialization of hemophilia and narcolepsy therapies, this indicator reflects the annual revenue dynamics over the last 12 months. The metric calculates the daily change in sales rates, neutralizing short-term market noise. By analyzing the current YoY revenue growth rate on a TTM basis, an investor can identify the real demand for innovative drugs. A stable upward trend confirms the fundamental resilience of the business model.